培美曲塞与卡铂共同治疗非小细胞肺癌患者的效果探讨

Investiqution on the Effect of Pemetrexed Combined with Carboplatin in the Treatment of Non-small Cell Lung Cancer

目的探讨培美曲塞与卡铂共同治疗非小细胞肺癌患者的效果。方法方便选取该院2017年4月-2019年4月期间收治的60例非小细胞肺癌患者进行研究,根据治疗方式的不同进行分组,对照组30例,采用吉西他滨联合卡铂治疗,观察组30例,采用培美曲塞联合卡铂治疗,对两组的治疗效果进行比较。结果观察组与对照组治疗总有效率比较差异无统计学意义(50.0%vs 46.7%)(χ^2=0.070,P=0.796);观察组患者肿瘤进展时间、平均生存期分别为(6.1±0.4)月、(11.5±0.8)月;对照组分别为(6.0±0.6)月、(11.7±0.9)月;两组对比差异无统计学意义(t=0.760、0.910,P=0.225、0.183);观察组血小板减少、白细胞减少、中性粒细胞减少、腹泻、口腔炎、恶心呕吐、脱发发生率分别为10.0%、3.3%、6.7%、6.7%、3.3%、6.7%、3.3%;对照组分别为33.3%、20.0%、30.0%、26.7%、20.0%、26.7%、20.0%;观察组均低于对照组(χ^2=4.810、4.040、5.450、4.320、4.040、4.320、4.040,P=0.028、0.044、0.020、0.038、0.044、0.038、0.044)。结论予以非小细胞肺癌患者培美曲塞与卡铂联合治疗效果显著,可改善患者病情,且可减少不良反应发生,具有推广价值。

Objective To investigate the effect of pemetrexed combined with carboplatin in the treatment of non-small cell lung cancer(NSCLC).Methods Convenient selection sixty patients with non-small cell lung cancer admitted to the hospital from April 2017 to April 2019 were enrolled.The patients were divided according to different treatment methods.30 patients in the control group were treated with gemcitabine plus carboplatin.Observation group 30 For example,pemetrexed in combination with carboplatin was used to compare the therapeutic effects of the two groups.Results There was no statistically significant difference in the total effective rate between the observation group and the control group(50.0%vs46.7%)(χ^2=0.070,P=0.796).The time of tumor progression and mean survival of patients in the observation group were(6.1±0.4)months and(11.5±0.8)months,respectively.The control group was(6.0±0.6)months and(11.7±0.9)months,respectively.There was no statistically significant difference between the two groups(t=0.760,0.910,P=0.225,0.183).In the observation group,the incidence of thrombocytopenia,leukopenia,neutropenia,diarrhea,stomatitis,nausea and vomiting,and hair loss were 10.0%,3.3%,6.7%,6.7%,3.3%,6.7%and 3.3%,respectively.The control group was 33.3%,20.0%,30.0%,26.7%,20.0%,26.7%and 20.0%,respectively.The observation group was lower than the control group(χ^2=4.810,4.040,5.450,4.320,4.040,4.320,4.040,P=0.028,0.044,0.020,0.038,0.044,0.038,0.044).Conclusion Pemetrexed combined with carboplatin in the treatment of non-small cell lung cancer is effective,which can improve the patient’s condition and reduce the occurrence of adverse reactions.